ArticleThe Lancet. Microbe2022

Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial.

Daniel Jenkin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.